SOPHiA GENETICS
Provider of a cloud-native analytics platform that applies machine learning to integrate and analyze multimodal clinical data (genomics, imaging and clinical records). Offers standardized bioinformatics pipelines, clinical workflows and reporting, regulatory-compliant data handling, and professional services for assay co-development, analytical validation, and deployment of scalable diagnostic and real-world evidence solutions.
Industries
Nr. of Employees
large (251-1000)
SOPHiA GENETICS
Patents
Methods for detecting copy-number variations in next-generation sequencing
US-12731658-B2
View DetailsMethods for DNA library generation to facilitate the detection and reporting of low frequency variants
US-12674158-B2
View DetailsMethods for detecting variants in next- generation sequencing genomic data
US-12573472-B2
View DetailsMethods for asymmetric DNA library generation and optionally integrated duplex sequencing
US-12297490-B2
View Details
Methods for detecting copy-number variations in next-generation sequencing
US-12731658-B2
View DetailsMethods for DNA library generation to facilitate the detection and reporting of low frequency variants
US-12674158-B2
View DetailsMethods for detecting variants in next- generation sequencing genomic data
US-12573472-B2
View DetailsMethods for asymmetric DNA library generation and optionally integrated duplex sequencing
US-12297490-B2
View DetailsProducts
IVD-certified genomics analytics for defined indications
In vitro diagnostic software solutions certified for specific oncology and hereditary indications in markets recognizing those certifications; the same platform can be used in Research Use Only mode where applicable.
Research-use analytics and variant-interpretation modules
Research-use-only analytics modules and interpretation tools for exome and genome analysis, variant review and knowledge-base driven interpretation for research and laboratory use.
IVD-certified genomics analytics for defined indications
In vitro diagnostic software solutions certified for specific oncology and hereditary indications in markets recognizing those certifications; the same platform can be used in Research Use Only mode where applicable.
Research-use analytics and variant-interpretation modules
Research-use-only analytics modules and interpretation tools for exome and genome analysis, variant review and knowledge-base driven interpretation for research and laboratory use.
Services
Cloud-hosted analytics and interpretation services for genomic, imaging and multimodal clinical data delivered to healthcare institutions, clinical laboratories and biopharma partners.
Collaborative programs with academic, clinical and industry partners to co-develop NGS assays, clinical trial assays and companion diagnostics, including support for validation and clinical translation.
Consulting services to support clinical deployment, analytical validation studies, workflow optimization and regulatory/quality system preparation for diagnostic assays and analytic software.
Cloud-hosted analytics and interpretation services for genomic, imaging and multimodal clinical data delivered to healthcare institutions, clinical laboratories and biopharma partners.
Collaborative programs with academic, clinical and industry partners to co-develop NGS assays, clinical trial assays and companion diagnostics, including support for validation and clinical translation.
Consulting services to support clinical deployment, analytical validation studies, workflow optimization and regulatory/quality system preparation for diagnostic assays and analytic software.
Expertise Areas
- Clinical genomics and variant interpretation
- Precision oncology analytics
- Bioinformatics pipeline development for NGS and RNA-seq
- Liquid biopsy and ctDNA analysis
Key Technologies
- Next-generation sequencing (NGS) analysis
- RNA-sequencing (RNA-seq) analysis
- Machine learning and deep learning for biomedical data
- Cloud-native analytics and distributed compute (CPU/GPU)
News & Updates
In-person forum at ESMO 2026 focused on liquid biopsy, decentralized testing, next-generation biomarkers, strategic partnerships and validation practices in precision oncology.
Announcement of a strategic collaboration to combine AI-powered analytics with clinical expertise to co-develop NGS oncology tests, RNA-seq bioinformatics and joint R&D programs.
Announcement that the analytics platform received certification under the European IVDR, validating the platform's diagnostic mode and confirming compliance with IVDR requirements for genetic analysis in markets recognizing IVDR.
Expansion of a collaboration using AI and multimodal data to improve detection of biomarkers and support precision oncology research and clinical development.
Partnership combining centralized companion diagnostic regulatory expertise with a decentralized, data-driven analytics platform to co-develop liquid biopsy CDx offerings.
Partnership with a local laboratory and market-access partner to enable broader liquid biopsy testing and support CDx commercialization in Japan.
In-person forum at ESMO 2026 focused on liquid biopsy, decentralized testing, next-generation biomarkers, strategic partnerships and validation practices in precision oncology.
Announcement of a strategic collaboration to combine AI-powered analytics with clinical expertise to co-develop NGS oncology tests, RNA-seq bioinformatics and joint R&D programs.
Announcement that the analytics platform received certification under the European IVDR, validating the platform's diagnostic mode and confirming compliance with IVDR requirements for genetic analysis in markets recognizing IVDR.
Expansion of a collaboration using AI and multimodal data to improve detection of biomarkers and support precision oncology research and clinical development.
Partnership combining centralized companion diagnostic regulatory expertise with a decentralized, data-driven analytics platform to co-develop liquid biopsy CDx offerings.
Partnership with a local laboratory and market-access partner to enable broader liquid biopsy testing and support CDx commercialization in Japan.